Hemp 15 mg & 50 mg Capsule Absorption

Overview

This study is intended to investigate the absorption of cannabidiol (CBD) and cannabidiol acid (CBD-A) in plasma from an oral delivery of a single dose of full spectrum hemp extract at two concentrations over a 4-hour timeline.

Full Title of Study: “Hemp 15 mg & 50 mg Capsule Absorption”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 2022

Detailed Description

This study is designed to determine the time to maximum plasma concentration of CBD and CBD-A after an oral dose of standardized full spectrum hemp extract over a 4-hour timeline. This study is designed to include two arms. Each arm will be delivered a different concentration of standardized full spectrum hemp extract, either 15 mg or 50 mg. Throughout the course of the study all participants will be asked to provide four (4) plasma samples, 10 randomly selected participants will be asked to provide five (5) plasma samples. Samples will then be evaluated using a validated LC-MS/MS method to develop a blood concentration time curve in order to determine time to reach maximum blood concentration. This trial is double-blinded with two arms enrolling only healthy individuals. The participants randomized for a fifth blood draw will be randomly selected from these two arms.

Interventions

  • Dietary Supplement: 15 mg/g Full Spectrum Hemp Extract
    • HPMC capsules containing full spectrum standardized hemp extract in liquid form.
  • Dietary Supplement: 50 mg/g Full Spectrum Hemp Extract
    • HPMC capsules containing full spectrum standardized hemp extract in liquid form.

Arms, Groups and Cohorts

  • Experimental: 15 mg/g Full Spectrum Hemp Extract
    • A single capsule of 15 mg/g Full Spectrum Hemp Extract will be delivered.
  • Experimental: 50 mg/g Full Spectrum Hemp Extract
    • A single capsule of 50 mg/g Full Spectrum Hemp Extract will be delivered.

Clinical Trial Outcome Measures

Primary Measures

  • Time to maximum plasma concentration
    • Time Frame: Over 4 hours
    • To determine the time to maximum plasma concentration of cannabidiol (CBD) and cannabidiol acid (CBD-A) from an oral delivery of a single dose of standardized 15 mg or 50 mg full spectrum hemp extract

Secondary Measures

  • Detectable THC
    • Time Frame: Over 4 hours
    • To determine if the oral delivery of a full spectrum hemp extract standardized to less than 0.3% ∆^9- tetrahydrocannabinol (THC) results in detectable amounts of THC in plasma.

Participating in This Clinical Trial

Inclusion Criteria

1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Ages 18 – 65. 4. In good general health as evidenced by medical history as indicated by oral confirmation of study participant. 5. Ability and willingness to suspend the use of any other herbal dietary supplements for 48 hours prior the first clinical visit associated with this study. 6. Ability and willingness to abstain from alcohol use for 12 hours prior to the first clinical visit. 7. Cannabis and CBD naïve for 60 days or more prior to enrolling in the study. 8. Ability and willingness to abstain from food for 6 hours prior to the first clinical visit. Exclusion Criteria:

1. Current use of regular medication for a chronic condition. 2. Current pregnancy or lactation. 3. Plans to become pregnant during the intended duration of the study. 4. Known allergic reactions to hemp flower. 5. Known severe food allergies.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Gaia Herbs Inc.
  • Collaborator
    • Appalachian College of Pharmacy
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Faisal Hossain, PhD, 276-498-5240, mhossain@acp.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.